Selected Reads

Smartkarma

Equity Bottom-Up

Alpine Immune is a small-to-mid cap biotech focused on immunology diseases, both common and rare. Its lead asset is ALPN-303, a BAFF/APRIL inhibitor initiating development on a likely-registrational Phase 2...<a target="_blank" href="https://www.valueinvestorsclub.com/idea/ALPINE_IMMUNE_SCIENCES_INC/7377618160">Read the article on Value Investor Club »</a>

United States

Alpine Immune Sciences, Inc. (AIS) focuses on developing novel protein-based cancer immunotherapies using its proprietary variant ig domain (vIgD) platform technology. The Company develops TIP technology, based on the vIgD platform, to enhance engineered cellular therapies. AIS offers a platform to interact with multiple targets, including many present in the immune synapse.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00